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Abstract

A series of new compounds with quinazolin-4-one structure, synthesized by the
Pharmaceutical Chemistry Department of the Faculty of Pharmacy of the University of
Medicine and Pharmacy “Carol Davila” Bucharest, was studied. Five of them were
selected, conventionally named S1, S2, S3, S4, S5, and investigated in terms of their
potential influence on the central nervous system (CNS). For this purpose, the
antidepressant effect was determined using the forced swimming test; the anxiolytic/
anxiogenic effect was determined using the suspended plus-shaped maze (Ugo Basile);
the effect on the motor activity was determined using the Ugo Basile activity cage; and
the potential analgesic effect was investigated using the hot plate test (Ugo Basile).
Compounds S3 and S5 lowered the motor activity and showed an anxiolytic effect, while
S1 and S2 proved to have antidepressant and analgesic effects.
A good correlation between antidepressant and analgesic effects was observed,
consistent with the fact that analgesic drugs, by increasing norepinephrine and serotonin
levels in the pain inhibiting descendent pathways, can be used as co-analgesics in
therapy.
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Highlights

 S1 and S2 reduced the immobilization time in the forced swimming test by 25.98%,
respectively 28.45%
 S3 and S5 have been shown to have relatively similar pharmacological profiles with
respect to influence on HMA and VMA
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Introduction
Quinazolone derivatives have been studied in
preclinical and clinical trials for many and various
therapeutic purposes: antidepressant (1), anticonvulsant
(2), analgesic (3), antineoplastic (4), antihypertensive (5),
or tuberculostatic (6). Moreover, there are several
approved drugs which belong to the carbamate ester
derivatives class, many of them with cholinergic actions:
physostigmine, neostigmine, or rivastigmine.
The new compound series, synthesized in the
Pharmaceutical Chemistry Laboratory of the Faculty of
Pharmacy within UMF “Carol Davila” Bucharest, brought
together the 4(3H)-quinazolinone structure and carbamic
ester group (7).

Table 1. Chemical structure of S1- S5 compounds

Compound

O
N
N

R
C

S1
O

NH NH2

CH2 R

CH3

Chemical name
2-(2-Methyl-4oxochinazolin-3(4H)-yl)acetohydrazide

S2

1-[(2-Methyl-4oxochinazolin-3(4H)-yl)methyl]-3-(3bromophenyl)-urea

S3

2-[2-(2-Methyl-4oxochinazolin-3(4H)-yl)acetyl]-hydrazino-N-(4methoxyphenyl)carbothioamide

S4

2-Methyl-3-[(5-phenylamino)-1,3,4-thiadiazole2-yl)-methyl]-chinazolin4(3H)-on

S5

2-Methyl-3-[(N-(3,5dimethoxyphenyl)carbonyl-oxy)carbamoyl-methyl]chinazolin-4(3H)-on

protocols of the Laboratory of Pharmacology, the Faculty
of Pharmacy, UMF “Carol Davila” Bucharest. We
investigated the antidepressant effect using the forced
swimming test, the anxiolytic/ anxiogenic effect using the
suspended plus-shaped maze (Ugo Basile), the effect on
the motor activity with the Ugo Basile activity cage, and
the potential analgesic effect using the hot plate test, Ugo
Basile (14).

Materials and Methods
A sample consisting of 94 white males, NMRI mice
having reached maturity and weighing 25 ± 2.8 g, were
supplied by the rodent farm of the University of Medicine
and Pharmacy “Carol Davila”. Animals were quarantined
for 3 days, and afterward, housed in ventilated cages with
free access to food and water. Temperature and relative
humidity were kept constant (22-24oC, 45-60%).
All experimental procedures were carried out in
accordance with the Directive 2010/63/UE of September
22nd, 2010, regarding the protection of animals used for
experimental and other scientific purposes. All
experimental procedures were approved by the Ethical
Committee of the Faculty of Pharmacy Bucharest. The
experiment was conducted in June 2014.
For the purpose of selecting the proper animals for the
proposed pharmacological tests, 94 mice were subjected
to the Ugo Basile activity cage test and divided into
groups based on their horizontal motor activity, measured
every 5 minutes. After exclusion of animals with extreme
responses, 84 mice remained and were divided into 7
groups, each containing 12 individuals in such a manner
that the average responses and the standard deviations
were as similar as possible. Animals were then allowed
one day for acclimation within their new groups. On the
day of the experiment, each group was brought to the lab,
one hour before the beginning of the experiment, to allow
them to adapt to the new environment where they were
kept without food.
The compounds were administered as shown below:

This synthesis resembles other similar processes that
are part of the recent research directions of the Discipline
of Pharmaceutical Chemistry, with the purpose of
obtaining new chemical compounds with potential
pharmacological actions (8-13).
In this paper, we present the results of the preclinical
research performed on these five new compounds in order
to assess the potential pharmacological actions on the
central nervous system. We followed all the existing
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• Group I (control) – distilled water 0.1 ml/10g orally
• Group II (reference) – amitriptyline 10 mg/kg bw susp.
0.1% orally
• Group III – S1 100 mg/kg bw, susp. 1% orally
• Group IV – S2 100 mg/kg bw, susp. 1% orally
• Group V – S3 100 mg/kg bw, susp. 1% orally
• Group VI – S4 100 mg/kg bw, susp. 1% orally
• Group VII – S5 100 mg/kg bw, susp. 1% orally
One hour after treatment, the mice were subjected to
the activity cage test to determine their motor activity and
then to the forced swimming test, in order to determine
the potential antidepressant effect of the new compounds.

Experimental research regarding quinazolin-4-ones derivatives
One week after the first set of tests (considered
enough time for the compounds to have been purged from
the system), all groups received the same treatment again
and were subjected first to the suspended cross-maze test
in order to determine the levels of anxiety, and then to the
hot plate test, in order to evaluate the potential analgesic
effects of the researched compounds.
All tests were conducted in accordance with the
following protocol: in the testing chamber, animals were
kept in artificial light, without food. Each individual was
administered the treatment with a 7-minute delay from the
previous one (5 minutes for the test itself and 2 minutes to
clean the device before testing the next animal) so that all
could be tested after the same time interval from the
moment of receiving the treatment.
The determination of the motor activity to assess the
effect on the central nervous system by recording the
horizontal and vertical movements of mice in the Activity
Cage Ugo Basile was performed by placing a mouse in a
corner of the device and monitoring its movements for 5
minutes.
The determination of the immobility time of mice in
forced swimming test (FST) was accomplished by placing
each mouse in a glass cylinder (25 cm height, 30 cm
diameter) containing a 20 cm high column of water at a
temperature of 22 ± 1oC and recording during a 4-minute
interval after a prior 2-minute interval for adaptation (15).

The determination of curiosity used the suspended
cross-shaped maze and involved placing the mouse in the
center of the device and measuring the time spent in the
open arms compared to the time spent in the enclosed
arms during a 5-minute interval.
The evaluation of pain sensitivity was performed using
the hot-plate test which consists of placing the mouse on a
metal plate heated to a 53oC temperature and measuring
the latency to the mouse’s reaction of licking its forepaws
or of trying to escalate the Plexiglas walls of the plate.
Statistical analysis
Statistical analysis used the software GraphPad Prism 5.
Comparison between groups used the Student t test (for
normal distribution) whereas comparison across multiple
groups used ANOVA. When significant, the Bonferroni
posttest adjustment was performed for posthoc
comparisons. The normality of the response distribution
in collectivity was tested with the D’Agostino & Pearson
test.

Results and Discussions
Group forming
The 84 mice remaining after excluding 10 individuals
with extreme responses were divided in 7 homogenous
groups, each containing 12 individuals. Their baseline
motor activity is shown below.
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All of the newly synthesized quinasolines reduced
the motor activity. S5 had the most intense effect,
inducing a 29.08% reduction in HMA and a 37.78%
reduction in VMA compared to the control group, which
were statistically significant.
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S3 also had an intense effect, but the reduction of the
motor activity in this case was not statistically significant.
Amitriptyline, which was used as the reference substance,
did not influence significantly the motor activity after the
acute administration.

Experimental research regarding quinazolin-4-ones derivatives
The forced swimming test was performed after acute
treatment, with this test giving positive results even after a
single dose, in the case of classical antidepressant drugs.

The average immobilization time for each group and
the effect compared to the control group is shown in the
following figure.

As expected initially, Amitriptyline reduced the
immobilization time by 23.85% compared to controls.
The result however was not statistically significant,
probably due to the large within-group variance.
The antidepressant effect of Amitriptyline is well
documented in the scientific literature (7, 16). Among the
tested compounds, the highest reduction in the

immobilization time was induced by S2, thus indicating
that it has the most intense antidepressant effect
(28.45%; p<0.05 – ANOVA + Bonferroni posttest).
Similarly, S1 reduced the immobilization time by
25.98%. The other three compounds proved to have no
significant antidepressant effect after only one
administration.
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In the suspended cross-maze test, neither of the
tested compounds induced statistically significant
changes. However, S3 resulted in a 44.35% increase in
the time spent in the open arms, and S5 had a similar
effect (34.36%). Acknowledging the fact that, under
the influence of anxiolytic drugs, mice tend to spend
more time in the open arms than the enclosed ones
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further suggests that S3 and S5 might have such an
effect. Another parameter that can give information
regarding the anxiolytic potential of a new substance is
the number of exits performed by mice outside the
open arms. The mean, standard deviations, and
comparison with the control group for this parameter
are shown below.

Experimental research regarding quinazolin-4-ones derivatives

The results confirm that these 2 compounds (S3 and S5)
have the highest anxiolytic potential, S3 having increased the

number of exits by 13.9% compared to the control group,
while S5 shows a similar and stronger pattern, 18.24%.
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S1 has the most intense analgesic effect compared to
the control group (79.03%, p<0.01, ANOVA +
Bonferroni) and also to the reference group (61.87%,
p<0.05, ANOVA + Bonferoni). S2 also delayed the first
pain reaction by 58.76% compared to the control group,
while S4 delayed by 53.69%. S3 and S5 had negligible
analgesic effects (17, 18).
Amitriptyline used as a reference had a low
analgesic effect after a single dose of 10 mg/kg bw. This
result is consistent with the other reports (19, 20).
The scientific literature also mentions the use of
tricyclic antidepressants as co-analgesics in the treatment
of some forms of pain (21).

Conclusions
The five new quinasolines tested in this study
induced various changes in the parameters investigated in
the preclinical tests conducted.
S3 and S5 proved to have similar pharmacological
profiles in that while S3 lowered HMA by 20% and VMA
by 28.01% compared to the control group, S5 had the
same effect on HMA (29,8%; P<0.01 - ANOVA +
Bonferroni) and to VMA, which was lowered by 37.78%
compared to the control group.
The same 2 compounds showed the most intense
anxiolytic potential by increasing the time spent in the
open arms of the cross-maze (S3: 44.35%; S5: 34.36%)
on one hand, and, on the other hand, the number of exits
from the open arms (S3: 13.9%; S5: 18.24%). However,
S3 and S5 had no antidepressant or analgesic effect.
S1 and S2 reduced the immobilization time in the
forced swimming test by 25.98% and 28.45% respectively
(p<0.05%; ANOVA + Bonferroni). The same 2
compounds also registered the most intense analgesic
effects compared to the control group (S1: 79.03%,
p<0.01; S2: 58.76%). S1 had a significant analgesic effect
also compared to amitriptyline (61.87%, p<0.05%;
ANOVA + Bonferroni).
A good correlation between the antidepressant and
the analgesic effects was observed, which is consistent
with the fact that analgesic drugs, by increasing the
norepinephrine and serotonin levels in the pain inhibiting
descendent pathways, can be used as co-analgesics in
therapy.
From our analyses, we confirm that the tested
compounds have high pharmacological potential worthy
of further investigation.
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